CTNM vs NVS
CTNM: Contineum Therapeutics is a clinical-stage biotech developing small molecule therapies for neuroscience, inflammation, and immunology. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | CTNM | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $15.49 | $156.11 | |
| Market cap as of 2026-08-03 | $358M | $232.1B | |
| P/E as of 2026-08-03 | n/a | 22.53 | |
| PEG as of 2026-08-03 | n/a | 3.66 | |
| Net margin as of 2026-08-03 | +45.4% | +22.5% | CTNM higher |
| Gross margin as of 2026-08-03 | n/a | +75.0% | |
| Operating margin as of 2026-08-03 | +32.1% | +29.9% | CTNM higher |
| ROE as of 2026-08-03 | -27.1% | +29.9% | NVS higher |
| ROA as of 2026-08-03 | -25.6% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-03 | 0.00 | 1.18 | CTNM lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | +3.3% | |
| Dividend yield as of 2026-08-03 | n/a | +2.9% | |
| Beta as of 2026-08-03 | 0.70 | 1.17 | |
| 1-year return as of 2026-07-31 close | +162.5% | +32.6% | CTNM higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.